Session Description:

Terumo is a medical device company offering diverse medical devices and services in more than 160 regions and countries for over 100 years. Terumo started diabetes business in 1982 and has continuously developed and launched various blood glucose meters and needles for pen injectors. In 2018, we launched a CGM and an insulin patch pump in Japanese market to meet the various needs of patients and health care professionals. Furthermore, we launched our insulin patch pump in European market in 2021.

In this symposium, we will present our detachable insulin patch pump “MEDISAFE WITH”. Five presenters will speak about the following topics:

 Clinical experience of MEDISAFE WITH in Japan

 Clinical experience of MEDISAFE WITH in Italy with two different patient segments

 Accuracy evaluation of patch pump

 Current AID system and future expectations for integration with patch pump

MEDISAFE WITH can provide various essential values to the patients, health care professionals and environment with an “USABILITY, RELIABILITY, SUSTAINABILYTY” concept. With our philosophy of “Your Courage, Our Care”, Terumo is proud to stand beside diabetes patients, providing the services and to support a happier life. We hope all of you enjoy this symposium.

Session Description:

This session will focus on emerging digital, real time-, and flash-based technologies for continuous monitoring of glucose levels, to improve drug interventions for persons with Type 2 and Type 1 diabetes, minimize risks of hypoglycemia, maximize time in target range for blood glucose, and to optimize treatment interventions and drug titration and selection. The international expert faculty will discuss the expanding foundational role and practical aspects of deploying flash-based technology to optimize metabolic health metrics and clinical outcomes in persons with diabetes; the role of CGM-based glycemic management in the age of telemedicine and Covid-19; the evolving mandate and evidentiary basis for deploying flash-based glycemic monitoring in persons with non-insulin managed type 2 diabetes; and will provide a CGM-based “best practice/best outcome” roadmap for persons across the full spectrum of diabetes.

Session Description:

Learn about innovations in insulin delivery, with the Omnipod® System. Gain a deeper understanding of the emerging clinical data to support the Omnipod® 5 Automated Insulin Delivery System and the value of customization in different patient cohorts. This event will be led by Dr. Trang Ly, Dr. Anders Carlson and Dr. Sarah MacLeish will co-present.

Session Description:

This symposium will introduce Tempo™, a Personalized Diabetes Management System and Lyumjev®, a fast-acting mealtime insulin from Eli Lilly.

Tempo integrates insulin dosing data with technology to help simplify diabetes management. Digital health technologies can help improve patient data visibility, physician-patient collaboration, clinical decision-making, and patient self-management, ultimately leading to better outcomes.

Faculty will discuss the complexities of insulin management, and how insulin dosing data may help facilitate communication between you and the people you treat. Automating insulin dosing data may help:

• Gain an understanding of their management patterns

• Stay informed between office visits

• Feel empowered to engage in shared decision-making

Lyumjev is a formulation of insulin lispro indicated to improve glycaemic control in adults with diabetes by enabling accelerated absorption.

Faculty will discuss the clinical profile of Lyumjev and how it:

• Has the fastest insulin absorption and a shorter duration of exposure when compared to other rapid-acting insulins

• Helps reduce post-prandial glucose without increased risk of hypoglycaemia

• Significantly outperformed Humalog when dosed at the start of a meal

This program is for all healthcare professionals treating people with diabetes on multiple daily injections of mealtime insulin.

Session Description:

Innovation of technology in type 1 diabetes has transformed the therapy and significantly improved both clinical and patient related outcomes. This symposium, chaired by Prof. Chantal Mathieu, will focus on extending the use of the MiniMed™ 780G system to the wider population of people with type 1 diabetes, in terms of clinical outcomes, patient related outcomes, and economic value. The results of three studies evaluating the MiniMed™ 780G system will be presented for the first time: Prof. Pratik Choudhary will discuss the transition of people not achieving the treatment goals with MDI and isCGM, followed by Prof. Tomasz Klupa who will address the transition of those totally naïve to pump or CGM technologies. The use of the MiniMed™ 780G system with Fiasp in the adolescent population during exercise, will be further discussed by Dr. Klemen Dovc.

Lastly, Prof. Ohad Cohen, Medical Director of Medtronic, will summarize the data presented and its implications on successfully achieving goals in growing populations and indications of people with type 1 diabetes.